Literature DB >> 15649565

Potential importance of error catastrophe to the development of antiviral strategies for hantaviruses.

Colleen B Jonsson1, Brook G Milligan, Jeffrey B Arterburn.   

Abstract

Hantaviruses represent an important and growing source of disease emergence in both established and developing countries. The New World hantaviruses have been touted as potential biological weapons because of their lethality to humans and high infectivity as an aerosol. It is also important to acknowledge the threat that hantaviruses can represent to US troops that operate in a foreign territory endemic for hantavirus infection, as was demonstrated in the Korean War. Effective vaccines, immunotherapeutics and antivirals for the prophylaxis or treatment of hantaviral infections are not available. Recent evidence that hantaviruses are prone to error catastrophe opens the door to the development of new therapeutic strategies. Possible future directions for applying lethal mutagenesis as a strategy for the development of novel and more effective antiviral therapies for treatment of hantavirus infections are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649565     DOI: 10.1016/j.virusres.2004.11.009

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  11 in total

Review 1.  Examining the theory of error catastrophe.

Authors:  Jesse Summers; Samuel Litwin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence.

Authors:  Ana Grande-Pérez; Gema Gómez-Mariano; Pedro R Lowenstein; Esteban Domingo
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Recognition of decay accelerating factor and alpha(v)beta(3) by inactivated hantaviruses: Toward the development of high-throughput screening flow cytometry assays.

Authors:  Tione Buranda; Yang Wu; Dominique Perez; Stephen D Jett; Virginie BonduHawkins; Chunyan Ye; Bruce Edwards; Pamela Hall; Richard S Larson; Gabriel P Lopez; Larry A Sklar; Brian Hjelle
Journal:  Anal Biochem       Date:  2010-04-02       Impact factor: 3.365

4.  Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.

Authors:  Yanjie Sun; Dong-Hoon Chung; Yong-Kyu Chu; Colleen B Jonsson; William B Parker
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

5.  The murine model for Hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment.

Authors:  Dong-Hoon Chung; Åke Västermark; Jeremy V Camp; Ryan McAllister; Susanna K Remold; Yong-Kyu Chu; Carl Bruder; Colleen B Jonsson
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

6.  Use of Saccharomyces cerevisiae-expressed recombinant nucleocapsid protein to detect Hantaan virus-specific immunoglobulin G (IgG) and IgM in oral fluid.

Authors:  Rasa Petraityte; Li Jin; Rashpal Hunjan; Ausra Razanskiene; Aurelija Zvirbliene; Kestutis Sasnauskas
Journal:  Clin Vaccine Immunol       Date:  2007-10-03

Review 7.  Quasispecies made simple.

Authors:  J J Bull; Lauren Ancel Meyers; Michael Lachmann
Journal:  PLoS Comput Biol       Date:  2005-11       Impact factor: 4.475

Review 8.  Mechanisms of action of ribavirin against distinct viruses.

Authors:  Jason D Graci; Craig E Cameron
Journal:  Rev Med Virol       Date:  2006 Jan-Feb       Impact factor: 6.989

9.  Person-to-person transmission of Andes virus.

Authors:  Valeria P Martinez; Carla Bellomo; Jorge San Juan; Diego Pinna; Raul Forlenza; Malco Elder; Paula J Padula
Journal:  Emerg Infect Dis       Date:  2005-12       Impact factor: 6.883

10.  Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus.

Authors:  Monica Ogg; Colleen B Jonsson; Jeremy V Camp; Jay W Hooper
Journal:  Viruses       Date:  2013-11-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.